More recently, mutations in TERT (telomerase reverse transcriptase) and CDKN2A (cyclin-dependent kinase inhibitor 2A) have been shown to be potential prognostic indicators in higher grade meningiomas [14,15]. The gene discussed is CDKN2A; the disease is meningioma.